Search results
Results from the WOW.Com Content Network
In a 2015 articles in the Journal of Urology, Thompson reported multi-parametric MRI detection of significant prostate cancer had sensitivity of 96%, specificity of 36%, negative predictive value and positive predictive values of 92% and 52%; when PI-RADS was incorporated into a multivariate analysis (PSA, digital rectal exam, prostate volume ...
Vickers is known for his research into prostate cancer screening. [6] In 2011, he published a study which found that PSA velocity—the change in the blood level of prostate-specific antigen (PSA)--was not a more accurate predictor of prostate cancer than comparing PSA levels to a specific threshold. [7]
SimBioSys anticipates FDA clearance for its breast cancer surgical planning tool in late 2023 with an expansion to other solid tumors to follow. Validation to lung and prostate cancer is already underway. While awaiting FDA approval, SimBioSys is commercializing the technology for use in patient education and drug development.
Prostate cancer antigen 3 is a urine test that detects the overexpression of the PCA3 gene, an indicator of prostate cancer. [32] [46] [47] [44] ConfirmMDx is performed on tissue taken during a prostate biopsy. The test identifies men with clinically significant prostate cancer who would benefit from further testing and treatment.
In 2000, Partin co-led a research team to reveal the differing prostate predication cancer risks amongst African American men and Caucasians. His team found that both groups of men could be spared prostate biopsies and instead use fPSA. [8] In 2005, Partin was appointed the David Hall McConnell Professor in the Department of Urology. [9]
The Gleason grading system is used to help evaluate the prognosis of men with prostate cancer using samples from a prostate biopsy. Together with other parameters, it is incorporated into a strategy of prostate cancer staging which predicts prognosis and helps guide therapy. A Gleason score is given to prostate cancer based upon its microscopic ...
A special service for people with kidney cancer was developed at the Royal Free Hospital, London, by surgeons whose training was funded by TUF. [36] TUF contributed funding into the research of 'PREDICT Prostate', a tool launched in 2019 and developed to predict a person's personalised prognosis following a diagnosis of prostate cancer. [37]
A histopathologic diagnosis of prostate cancer is the discernment of whether there is a cancer in the prostate, as well as specifying any subdiagnosis of prostate cancer if possible. The histopathologic subdiagnosis of prostate cancer has implications for the possibility and methodology of any subsequent Gleason scoring . [ 1 ]